Category - Feature

Feature

Sebastian Hadjiantoniou of Incuvers discusses accelerating cellular research

As a co-founder and CEO of closely-held Incuvers, an early-stage life sciences company developing a sophisticated incubator for cellular biologists, Sebastian Hadjiantoniou knows firsthand the rocky journey from...

October 1, 2019

Feature

INmune Bio harnessing innate immune system against cancer, neurodegenerative diseases

INmune Bio (NASDAQ:INMB) is developing new therapies that modulate the innate immune system, the body’s first line of defense against pathogens, to treat cancer and neuroinflammation that lead to neurodegenerative...

September 24, 2019

Feature

DelMar Pharma developing VAL-083 in biomarker-driven GBM patient populations

DelMar Pharmaceuticals (NASDAQ:DMPI) is conducting two Phase 2 clinical trials with its lead drug candidate, VAL-083, a DNA-targeting agent, in three distinct biomarker-driven glioblastoma multiforme (GMB) patient...

September 10, 2019

Feature

Interface Biologics sells Endexo surface modification business, sharpens focus on Epidel drug delivery platform

Closely-held Interface Biologics is selling its Endexo surface modification business and shifting its focus to its Epidel drug delivery technology, initially for ophthalmic indications.

September 3, 2019

Feature

Precipio aims to prevent misdiagnosis of blood-related cancers

Using a combination of advanced lab technologies, and a platform giving access to expert academic pathologists, Precipio (NASDAQ:PRPO) has staked out a unique position in its battle to prevent misdiagnosis of blood...

August 27, 2019

Feature

Beyond Air’s cylinder-free nitric oxide delivery system for respiratory conditions

Beyond Air (NASDAQ:XAIR), formerly AIT Therapeutics, is developing a proprietary nitric oxide (NO) generator and delivery system that uses NO generated from ambient air, rather than bulky cylinders, and delivers precise...

August 20, 2019

Feature

PharmAust readies pivotal trial in Australia to treat cancer in dogs

PharmAust (ASX:PAA) is gearing up to begin a pivotal Phase 2 study in Australia with its lead veterinary drug candidate, monepantel, for the treatment of lymphoma in canines, which if successful, could open the door to...

August 12, 2019

Feature

Theralase Phase 2 NMIBC clinical study could support marketing application

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) has designed its Phase 2 clinical study in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) based on FDA industry guidance issued in February 2018.

August 6, 2019

Feature

Hepion Pharmaceuticals’ CEO Robert Foster discusses CRV431’s potential in NASH

Hepion Pharmaceuticals (NASDAQ:HEPA), which recently changed its name from ContraVir Pharmaceuticals, is developing targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic...

July 30, 2019

Feature

PharmaCyte’s Cell-in-a-Box encapsulation technology targeting cancer, diabetes

PharmaCyte Biotech (OTCQB:PMCB) is developing cellular therapies for its lead pancreatic cancer program and for diabetes that are based on a proprietary cellulose-based live cell encapsulation technology known as a Cell...

July 23, 2019

Category - Feature

Subscribe